近日，成都市凯瑞医疗科技有限公司（以下简称"凯瑞医疗"）宣布完成Pre-A+轮融资。据了解，本轮投资由泸州老窖集团旗下华西证券全资直投 公司——华西银峰投资有限责任公司（以下简称"华西银峰"）独家投资。值得注意的是，这是继上一轮由泸州市双港实业投资发展有限公司对其 投资数千万元后，泸州国资体系在短时间内对凯瑞医疗进行的追加投资，完成本轮融资后，公司估值已超过2.5亿元。 凯瑞医疗创立于2022年，是多模态类人形医疗机器人企业，在采血、超声、AI视觉领域均有布局产品，核心产品是智能采血机器人（M系类）。据悉，公司 首款产品M1Pro已完成临床试验，正进行三类医疗器械注册许可证的申请流程，此外便携式采血机器人（M1mini）也已进入研发周期。 基于行业痛点和市场机遇 采血全流程仅需约90秒 血液检测作为临床诊断的标准，为超过70%的医疗决策提供关键依据，这使得采血成为全球医疗系统中最高频的刚需操作之一。但同时，面对全球2000多亿 元的庞大市场空间，当前采血领域却呈现出明显的供需失衡：一方面，临床面临婴幼儿、老年人群等特殊血管穿刺的痛点；另一方面，行业仍完全依赖人工 操作，缺乏真正成熟的产品，智能化渗透率几乎为零 ...

Group 1 - Chengdu Kairui Medical Technology Co., Ltd. has completed a Pre-A+ round of financing, with a valuation exceeding 250 million yuan after this round [1] - The investment was exclusively made by Huaxi Silver Peak Investment Co., Ltd., a wholly-owned subsidiary of Luzhou Laojiao Group [1] - Kairui Medical focuses on multimodal humanoid medical robots, addressing pain points in repetitive and high-intensity tasks in the medical field [1][3] Group 2 - The company's core product is the intelligent blood collection robot (M series), with the first product M1Pro having completed clinical trials and currently undergoing the registration process for Class III medical devices [1][3] - The portable blood collection robot (M1mini) is in the research and development phase, targeting a significant market space of over 200 billion yuan globally [3][5] Group 3 - Kairui Medical's blood collection robots aim to reduce pain and improve efficiency in blood collection, with a full process time of approximately 90 seconds [3][5] - The robots utilize dual infrared and ultrasound technology to enhance precision in blood vessel targeting, achieving sub-millimeter accuracy [5][6] Group 4 - The company is expanding its AI vision technology to various applications, including a collaboration with Beijing Scar Hospital to develop the S1 scar intelligent detection system [5][6] - The S1 system assists in monitoring scar treatment through multi-dimensional quantitative assessments [5] Group 5 - The recent financing will primarily be used for establishing clinical demonstration centers and accelerating data accumulation and product optimization [5][6] - Kairui Medical plans to promote a new medical scenario combining self-service blood collection and rapid report generation [5][6] Group 6 - The company aims to address public concerns about robot-assisted blood collection by enhancing user experience and comfort, including the development of a "pain-free needle" [6] - Kairui Medical emphasizes precision as a core technology, showcasing strong clinical adaptability across different age groups [6][7] Group 7 - Huaxi Silver Peak expressed confidence in the potential of intelligent puncture technology in medical automation, highlighting its social value and commercial potential [7]